Shanghai Bao Pharmaceuticals Co., Ltd. (2659.HK) AI-Powered Stock Analysis
See how Shanghai Bao Pharmaceuticals Co., Ltd. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
2659.HK●HKSE
HealthcareBiotechnology
HK$16.42
HK$0.26(1.61%)
Hong Kong Market opens in 39h 44m
Advertisement
Shanghai Bao Pharmaceuticals Co., Ltd. (2659.HK)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerShanghai Bao Pharmaceuticals Co., Ltd. (2659.HK) Stock Overall Grade
Shanghai Bao Pharmaceuticals Co., Ltd.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Shanghai Bao Pharmaceuticals Co., Ltd.'s overall stock rating.
Forecast
CScore
46/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Shanghai Bao Pharmaceuticals Co., Ltd. (2659.HK) AI-Powered Stock Analysis
This asset demonstrates Normal performance with an overall Forecast Score of 46/100 (C), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Shanghai Bao Pharmaceuticals Co., Ltd. stock grade, including financials, comparisons, and forecasts.